The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A cyclodepsipeptide that is N-[(3R)-3-hydroxy-14-methylpentadecanoyl]-L-alpha-glutamyl-L-leucyl-D-leucyl-L-valyl-L-alpha-aspartyl-D-leucyl-L-leucine in which the C-terminal carboxy group has been lactonised by condensation with the alcoholic hydroxy group.
Acetylcysteine inhibits the reaction [surfactin peptide results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in increased expression of BAX protein]
Acetylcysteine inhibits the reaction [surfactin peptide results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in decreased expression of BCL2 protein]
Acetylcysteine inhibits the reaction [surfactin peptide results in increased cleavage of and results in increased activity of CASP6 protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in increased cleavage of and results in increased activity of CASP6 protein]; surfactin peptide results in increased cleavage of and results in increased activity of CASP6 protein CASP6 protein affects the susceptibility to surfactin peptide
Acetylcysteine inhibits the reaction [surfactin peptide affects the localization of CYCS protein]; pyrazolanthrone inhibits the reaction [surfactin peptide affects the localization of CYCS protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; [tin protoporphyrin IX results in decreased activity of HMOX1 protein] results in decreased susceptibility to [surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of IL1B protein]]; [tin protoporphyrin IX results in decreased activity of HMOX1 protein] results in decreased susceptibility to [surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of IL6 protein]]; [tin protoporphyrin IX results in decreased activity of HMOX1 protein] results in decreased susceptibility to [surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of TNF protein]]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; Dactinomycin results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the susceptibility to [surfactin peptide results in increased expression of HMOX1 protein] surfactin peptide results in increased expression of HMOX1 mRNA; surfactin peptide results in increased expression of HMOX1 protein HMOX1 protein affects the susceptibility to surfactin peptide
[tin protoporphyrin IX results in decreased activity of HMOX1 protein] results in decreased susceptibility to [surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of IL1B protein]]; surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of IL1B protein]
[tin protoporphyrin IX results in decreased activity of HMOX1 protein] results in decreased susceptibility to [surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of IL6 protein]]; surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of IL6 protein]
[[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAPK1 protein] co-treated with [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAPK3 protein]] results in decreased susceptibility to surfactin peptide surfactin peptide results in increased expression of MAPK1 protein modified form
[[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAPK1 protein] co-treated with [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAPK3 protein]] results in decreased susceptibility to surfactin peptide surfactin peptide results in increased expression of MAPK3 protein modified form
NFE2L2 protein affects the susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; surfactin peptide affects the localization of and results in increased expression of NFE2L2 protein
[tin protoporphyrin IX results in decreased activity of HMOX1 protein] results in decreased susceptibility to [surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of TNF protein]]; surfactin peptide results in decreased susceptibility to [Lipopolysaccharides results in increased secretion of TNF protein]
browse the term
